For more information about how Boss Lawyers can assist with insolvency and restructuring matters, visit our Insolvency Lawyers Brisbane page or call Mark Harley on 1300 267 711.
The company grants a mortgage over its commercial property. The bank advances funds. The director’s personal guarantee is discharged. Everyone walks away satisfied — or so they think. Months later the company collapses, a liquidator is appointed, and the transaction is challenged as an unreasonable director-related transaction under s 588FDA of the Corporations Act 2001 (Cth). The argument: the company got nothing meaningful from the arrangement; it was the director who benefited — because their personal exposure to the bank evaporated.
That scenario is no longer theoretical. The Full Federal Court confirmed it in CEG Direct Securities Pty Ltd v Cooper (as liquidator of Runtong Investment and Development Pty Ltd (in liq)), and the High Court of Australia has now refused special leave to appeal. The broad reading of s 588FDA is settled law. Directors and their advisers need to understand what that means.
Background: What Is a Director-Related Transaction?
Section 588FDA of the Corporations Act allows a liquidator to void a transaction that satisfies two conditions:
- The transaction was entered into for the benefit of a director (or a close associate of a director); and
- A reasonable person in the company’s circumstances would not have entered into the transaction.
The provision sits within the broader voidable transactions regime alongside unfair preferences (s 588FA) and uncommercial transactions (s 588FB). Unlike unfair preferences — which require a creditor relationship — s 588FDA is specifically aimed at transactions that enrich those in control at the company’s expense.
Common examples include salary payments above market rate, loans to directors that are never repaid, and transfers of company assets to entities connected with a director. But CEG Direct Securities pushes the reach of the section considerably further.
The CEG Direct Securities Decision
In CEG Direct Securities v Cooper, the insolvent company had granted a mortgage over its assets. The critical effect of that mortgage was to discharge — or substantially reduce — the personal guarantee liability that the director owed to the secured creditor. The company received the advance, but the director shed personal exposure worth hundreds of thousands of dollars.
The liquidator challenged the transaction under s 588FDA. The primary question before the Full Federal Court was whether this arrangement was “for the benefit of a director” when the benefit was indirect — the director did not receive money or property directly from the company, but their personal financial position improved because of what the company did.
The Full Court held: indirect benefits count.
The Court gave a broad, purposive construction to s 588FDA. The phrase “for the benefit of a director” is not limited to direct transfers or payments. Any transaction that improves a director’s financial position — including the reduction or elimination of the director’s personal guarantee liability — can satisfy the requirement. The company’s act of granting security that discharged the director’s personal obligation to a creditor fell squarely within the provision.
What “Indirect Benefit” Means in Practice
The Full Federal Court’s reasoning has significant practical reach. Consider these scenarios — all now potentially caught by s 588FDA:
- A company grants a mortgage or charge over its assets, and the effect is to discharge or reduce a director’s personal guarantee to the same lender.
- The company makes a payment to a creditor under circumstances where the director was co-debtor or guarantor — the payment reduces the director’s exposure.
- The company enters into a refinancing arrangement that replaces a facility over which the director had provided personal security — and the director is released from that security as part of the transaction.
- The company grants security to a related party entity that is itself connected to a director — the director indirectly benefits through their interest in the related party.
In each case, the company may have received something of value (the advance, the refinancing), but if the transaction also had the effect of improving the director’s personal financial position, the “benefit” requirement of s 588FDA can be satisfied. The second limb — whether a reasonable person in the company’s circumstances would have entered into the transaction — then becomes the battleground.
That second limb asks whether the transaction made commercial sense from the company’s perspective, on its own merits, without weighting the benefit to the director. If the answer is no — if the company would not have entered into the transaction but for the benefit it conferred on the director — the liquidator has a strong case.
The High Court’s Refusal: Why It Matters
Special leave to appeal to the High Court was sought and refused. That refusal is significant for three reasons.
First, it confirms the Full Federal Court’s broad construction of s 588FDA as the authoritative position. Courts and practitioners across Australia will now apply it.
Second, it signals that the High Court saw no sufficient doubt in the lower court’s reasoning to warrant review. The purposive, broad reading was not a borderline call — it was a defensible, well-reasoned outcome.
Third, it removes uncertainty that might otherwise have allowed directors and pre-insolvency advisers to argue that the law remained unsettled. The position is now clear: transactions that indirectly benefit directors are within scope.
For insolvency practitioners, this is an expansion of the toolkit. For directors and their commercial advisers, it is a compliance alert.
What Directors Must Know Right Now
If your company is in financial difficulty, or if you are restructuring its debt obligations, pay close attention to the following:
- Review your guarantee position. If the company is entering into a transaction that will release or reduce a personal guarantee you have given, that transaction may later be challenged by a liquidator — even if the company received consideration at the time.
- Document commercial justification. Every significant transaction should be supported by contemporaneous evidence of why a reasonable person in the company’s position would have entered into it, independently of any benefit to directors. Minutes, advice, valuations, and board resolutions matter.
- Understand the look-back period. Section 588FDA applies to transactions within four years before the relation-back day (the commencement of winding up or administration). Transactions entered into now can be challenged years later.
- Don’t assume “good value” protects you. Even where a company receives fair consideration for a transaction, the provision can still apply if the transaction simultaneously conferred a benefit on a director that a reasonable person would not have accepted on the company’s behalf.
- Seek advice before restructuring. Pre-insolvency structuring that indirectly benefits directors — including guarantee releases, security substitutions, and debt consolidation — now warrants careful legal scrutiny before execution.
What Insolvency Practitioners Should Know
For liquidators and voluntary administrators, CEG Direct Securities is a material development:
- Expand your transaction review. When conducting the standard voidable transaction analysis, look beyond direct payments and asset transfers. Map every transaction in the four-year window against the director’s personal exposure — guarantees, co-debts, security arrangements — to identify where the director’s position improved as a company-side effect.
- Guarantees are a starting point. Bank lending in SME and mid-market transactions almost always involves personal director guarantees. Where a company refinanced, restructured, or granted additional security in the lead-up to insolvency, there is a strong prima facie case for scrutiny under s 588FDA.
- The reasonableness inquiry is commercial, not formalistic. The question is whether a reasonable person in the company’s circumstances — aware of its financial position, its obligations, and the terms on offer — would have entered into the transaction. Courts look at the commercial substance, not just the form.
- Recoveries may be available where unfair preference actions are not. Where the creditor received a preference but can establish the running account defence or commercial justification, s 588FDA may offer an alternative recovery pathway if a director benefit is identifiable.
- Document your reasoning. Given that s 588FDA proceedings involve both factual and commercial judgments, thorough file notes on why the practitioner formed the view that a transaction was voidable — and the legal analysis supporting it — will be critical if challenged.
How Boss Lawyers Can Help
Boss Lawyers is experienced in acting for liquidators, creditors, and directors in complex insolvency disputes, including voidable transaction proceedings. We focus on the serious end of commercial insolvency — contested clawback claims, director liability exposure, and pre-insolvency risk management.
Whether you are:
- a liquidator assessing a transaction for potential recovery under s 588FDA,
- a director who has received a demand or letter from a liquidator,
- a commercial adviser whose client is contemplating a restructure involving guarantee releases or security substitution, or
- a creditor seeking to understand how the decision affects your exposure,
we can provide practical, commercially-grounded advice on your position and your options.
The law in this area has moved. Directors and their advisers need to be ahead of it.
To discuss your situation, contact Mark Harley, Principal Solicitor, on 1300 267 711 or through our website at bosslawyers.com.au.
Boss Lawyers | Level 27, Santos Place, 32 Turbot Street, Brisbane QLD 4000 | 1300 267 711
For strategic advice on director duties, personal liability, and shareholder disputes, speak with our experienced director dispute lawyers Brisbane. Call Boss Lawyers on 1300 267 711 or complete our online enquiry form today.
Related Reading
This is general information only and is not legal advice. You should obtain professional advice specific to your circumstances. The law described above relates to the Corporations Act 2001 (Cth) and may be subject to change. Past results do not guarantee future outcomes.
